Education
About Us
Working with TipRanks
Follow Us
Globus Medical (GMED)
NYSE:GMED
GMED Stock Chart & Stats
Day’s Range― - ―
52-Week Range$49.33 - $94.93
Previous CloseN/A
Volume442.39K
Average Volume (3M)1.37M
Market Cap
$11.61B
Enterprise Value$11.20B
Total Cash (Recent Filing)$784.44M
Total Debt (Recent Filing)$537.19M
Price to Earnings (P/E)97.5
Beta1.00
Next Earnings
May 13, 2025EPS Estimate
0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding137,541,640
10 Day Avg. Volume1,321,356
30 Day Avg. Volume1,371,940
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.02
Price to Cash Flow (P/CF)12.00
P/FCF Ratio12.00
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.55
Enterprise Value/Ebitda21.83
Forecast
1Y Price Target
$98.75Price Target Upside36.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
---
Globus Medical News
See All GMED News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGMED finished the year strong, beating on both the top and bottom lines and generating record free cash flow.
Product LaunchGMED has remained on the offensive, pointing to a record number of new product launches in 2024 and more launches planned for 2025.
Regulatory ApprovalGMED's ExcelsiusFlex robotic system received FDA clearance for total knee arthroplasty, indicating regulatory approval and potential market entry.
Bears Say
Acquisition ImpactThe new NVRO deal will be dilutive in year 1 likely due to SG&A spend.
Earnings ImpactThe Nevro transaction initially results in an adjusted EPS dilution of $0.20 but is expected to be accretive in the second year.
Stock PerformanceGMED shares are down 9% since the announcement two weeks ago.
---
Ownership Overview
16.45% Insiders
30.69% Mutual Funds
0.69% Other Institutional Investors
31.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMED FAQ
What was Globus Medical’s price range in the past 12 months?
Globus Medical lowest stock price was $49.33 and its highest was $94.93 in the past 12 months.
What is Globus Medical’s market cap?
Globus Medical’s market cap is $11.61B.
When is Globus Medical’s upcoming earnings report date?
Globus Medical’s upcoming earnings report date is May 13, 2025 which is in 43 days.
How were Globus Medical’s earnings last quarter?
Globus Medical released its earnings results on Feb 20, 2025. The company reported $0.84 earnings per share for the quarter, beating the consensus estimate of $0.748 by $0.092.
Is Globus Medical overvalued?
According to Wall Street analysts Globus Medical’s price is currently Undervalued.
Does Globus Medical pay dividends?
Globus Medical does not currently pay dividends.
What is Globus Medical’s EPS estimate?
Globus Medical’s EPS estimate is 0.75.
How many shares outstanding does Globus Medical have?
Globus Medical has 137,541,640 shares outstanding.
What happened to Globus Medical’s price movement after its last earnings report?
Globus Medical reported an EPS of $0.84 in its last earnings report, beating expectations of $0.748. Following the earnings report the stock price went down -4.565%.
Which hedge fund is a major shareholder of Globus Medical?
Currently, no hedge funds are holding shares in GMED
---
Globus Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$98.75 (36.11% Upside)
$98.75 (36.11% Upside)
Blogger Sentiment
Bullish
GMED Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.25%
12-Months-Change
Fundamentals
Return on Equity
2.52%
Trailing 12-Months
Asset Growth
3.26%
Trailing 12-Months
Company Description
Globus Medical
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
---
GMED Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Globus Medical reported a strong financial performance with record revenue and growth, successful product launches, and impressive enabling technology sales. The company is achieving significant synergies from the NuVasive merger and is on track to become debt-free. However, there were some challenges, including supply chain disruptions and foreign exchange headwinds. Overall, the sentiment is positive due to the outweighing highlights.Read More>---
GMED Net sales Breakdown
92.34% Musculoskeletal Solutions
7.66% Enabling Technologies
---
GMED Stock 12 Month Forecast
Average Price Target
$98.75
▲(36.11% Upside)
Technical Analysis
Baxter International
―
Integra Lifesciences
―
Smith & Nephew Snats
―
Zimmer Biomet Holdings
―
Medpace Holdings
―
Best Analysts Covering GMED
1 Year
1 Year Success Rate
21/31 ratings generated profit
1 Year Average Return
+15.84%
reiterated a buy rating last month
Copying Matt Miksic's trades and holding each position for 1 Year would result in 67.74% of your transactions generating a profit, with an average return of +15.84% per trade.
---